Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, announced that it will present at two upcoming investor conferences.
WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at two upcoming investor conferences.
- The Stifel 2022 Healthcare Conference being held November 15-16 in New York. Jon K. Snodgres, Chief Financial Officer, will participate in an analyst-led discussion on Wednesday, November 16, at 2:25 p.m. EST.
- Stephens’ Annual Investment Conference being held November 15-17 in Nashville. Mr. Snodgres will participate in an analyst-led discussion on Thursday, November 17, at 2:00 p.m. EST.
A live webcast of the discussions will be accessible through the Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event.
About Repligen Corporation
Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration, Chromatography, Process Analytics, Fluid Management and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Hampshire, New Jersey and New York), and we also have sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company, including Repligen news releases, see our website at http://www.repligen.com. Follow us on LinkedIn and Twitter.
Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com
